NeuroDiscovery closes IPO
Friday, 12 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
NeuroDiscovery offered 7.5 million shares at an issue price of AUD$0.20 each to raise the $1.5 million. NeuroSolutions - which has a mature pipeline of programs for the treatment of pain - is expected to commence Phase I and II clinical trials in the next 18 months.
NeuroDiscovery expects to list on the ASX on Monday 15 August.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
